Your browser doesn't support javascript.
loading
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
Greene, Michelle K; Chen, Ting; Robinson, Eifion; Straubinger, Ninfa L; Minx, Charlene; Chan, Darren K W; Wang, Jun; Burrows, James F; Van Schaeybroeck, Sandra; Baker, James R; Caddick, Stephen; Longley, Daniel B; Mager, Donald E; Straubinger, Robert M; Chudasama, Vijay; Scott, Christopher J.
Afiliación
  • Greene MK; The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
  • Chen T; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Robinson E; Department of Chemistry, University College London, London, UK.
  • Straubinger NL; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Minx C; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Chan DKW; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Wang J; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Burrows JF; School of Pharmacy, Queen's University Belfast, Belfast, UK.
  • Van Schaeybroeck S; The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
  • Baker JR; Department of Chemistry, University College London, London, UK.
  • Caddick S; Department of Chemistry, University College London, London, UK.
  • Longley DB; The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
  • Mager DE; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Straubinger RM; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA. rms@buffalo.edu.
  • Chudasama V; Department of Pharmacology & Cancer Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA. rms@buffalo.edu.
  • Scott CJ; Department of Chemistry, University College London, London, UK. v.chudasama@ucl.ac.uk.
Br J Cancer ; 123(10): 1502-1512, 2020 11.
Article en En | MEDLINE | ID: mdl-32913288
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oligopéptidos / Neoplasias Pancreáticas / Inmunoconjugados / Cetuximab / Aminobenzoatos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oligopéptidos / Neoplasias Pancreáticas / Inmunoconjugados / Cetuximab / Aminobenzoatos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido